Rouzier developed and validated a nomogram, which was based on oestrogen receptor status, clinical stage, histologic grade and number of pre‐operative chemotherapy cycles to predict distant metastasis‐free survival.20 Cheng et al developed a robust 4‐gene signature (SRPK1, PCCA, PRLR and FBP1) to predict distant relapse‐free survival (DRFS) for patients with HER2‐negative breast cancer following taxane and anthracycline‐based chemotherapy. This evidence concerns the gene SRPK1 and breast carcinoma.